Revised international prognostic scoring system for myelodysplastic syndromes
- PMID: 22740453
- PMCID: PMC4425443
- DOI: 10.1182/blood-2012-03-420489
Revised international prognostic scoring system for myelodysplastic syndromes
Abstract
The International Prognostic Scoring System (IPSS) is an important standard for assessing prognosis of primary untreated adult patients with myelodysplastic syndromes (MDS). To refine the IPSS, MDS patient databases from international institutions were coalesced to assemble a much larger combined database (Revised-IPSS [IPSS-R], n = 7012, IPSS, n = 816) for analysis. Multiple statistically weighted clinical features were used to generate a prognostic categorization model. Bone marrow cytogenetics, marrow blast percentage, and cytopenias remained the basis of the new system. Novel components of the current analysis included: 5 rather than 3 cytogenetic prognostic subgroups with specific and new classifications of a number of less common cytogenetic subsets, splitting the low marrow blast percentage value, and depth of cytopenias. This model defined 5 rather than the 4 major prognostic categories that are present in the IPSS. Patient age, performance status, serum ferritin, and lactate dehydrogenase were significant additive features for survival but not for acute myeloid leukemia transformation. This system comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS. As such, this IPSS-R should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease.
Figures
Similar articles
-
International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.Am J Hematol. 2008 Oct;83(10):765-70. doi: 10.1002/ajh.21249. Am J Hematol. 2008. PMID: 18645988
-
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.J Clin Oncol. 2011 May 20;29(15):1963-70. doi: 10.1200/JCO.2010.28.3978. Epub 2011 Apr 25. J Clin Oncol. 2011. PMID: 21519021 Free PMC article.
-
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27. Leukemia. 2015. PMID: 25721895
-
A comparative review of classification systems in myelodysplastic syndromes (MDS).Semin Oncol. 2005 Aug;32(4 Suppl 5):S3-10. doi: 10.1053/j.seminoncol.2005.06.021. Semin Oncol. 2005. PMID: 16085011 Review.
-
Evaluating the prognosis of patients with myelodysplastic syndromes.Ann Hematol. 2002 Sep;81(9):485-97. doi: 10.1007/s00277-002-0530-z. Epub 2002 Sep 24. Ann Hematol. 2002. PMID: 12373348 Review.
Cited by
-
Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.Curr Treat Options Oncol. 2024 Jun;25(6):752-768. doi: 10.1007/s11864-024-01217-0. Epub 2024 May 30. Curr Treat Options Oncol. 2024. PMID: 38814537 Review.
-
Myelodysplastic Syndrome: Clinical Characteristics and Significance of Preclinically Detecting Biallelic Mutations in the TET2 Gene.Life (Basel). 2024 May 16;14(5):637. doi: 10.3390/life14050637. Life (Basel). 2024. PMID: 38792657 Free PMC article.
-
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).Hemasphere. 2024 May 21;8(5):e69. doi: 10.1002/hem3.69. eCollection 2024 May. Hemasphere. 2024. PMID: 38774655 Free PMC article. Review.
-
A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients.Front Pharmacol. 2024 May 2;15:1265840. doi: 10.3389/fphar.2024.1265840. eCollection 2024. Front Pharmacol. 2024. PMID: 38756378 Free PMC article.
-
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.Hemasphere. 2024 May 15;8(5):e64. doi: 10.1002/hem3.64. eCollection 2024 May. Hemasphere. 2024. PMID: 38756352 Free PMC article.
References
-
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088. - PubMed
-
- Malcovati L, Porta M, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria, a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594–7603. - PubMed
-
- Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503–3510. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous